血流感染症検査の世界市場2022-2030:機会分析・産業予測

◆英語タイトル:Blood Stream Infection Testing Market by Product (Instruments, Consumables, and Software & Services), Technique (Conventional and Automated), and Technology (Culture-based, Molecular, and Proteomic), Application (Bacterial, Fungal, and Mycobacterial), End-user (Hospitals, Independent Diagnostics Centers, and Others), and Regional Analysis (North America, Europe, Asia-Pacific and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022–2030

Research Diveが発行した調査報告書(RDV22DV005)◆商品コード:RDV22DV005
◆発行会社(リサーチ会社):Research Dive
◆発行日:2022年7月
◆ページ数:260
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,700 ⇒換算¥843,600見積依頼/購入/質問フォーム
5 UserUSD8,700 ⇒換算¥1,287,600見積依頼/購入/質問フォーム
Enterprise UserUSD10,700 ⇒換算¥1,583,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

リサーチダイブ社発行の当調査レポートでは、世界の血流感染症検査市場規模が2021年5,173.1百万ドルから2030年には10,540.8百万ドルまでに達し、年平均8.3%成長すると予測しています。当レポートは、血流感染症検査の世界市場について多面的に分析し、調査手法、調査範囲、エグゼクティブサマリー、市場概要、製品別(装置、消耗品、ソフトウェア&サービス)分析、技術別(従来型、自動)分析、技法別(培養法、分子法、プロテオミクス法)分析、用途別(細菌、真菌、マイコバクテリア)分析、地域別状況(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)、競争状況などの内容をまとめています。なお、参入企業情報として、Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Becton Dickinson, bioMérieux SA, Cepheid, Luminex Corporation, Accelerate Diagnostics Inc., AdvanDX, and Bruker Corp.などが含まれています。

・調査手法
・調査範囲
・エグゼクティブサマリー
・市場概要

・世界の血流感染症検査市場規模:製品別
- 血流感染症検査装置の市場規模
- 血流感染症検査消耗品の市場規模
- 血流感染症検査ソフトウェア&サービスの市場規模

・世界の血流感染症検査市場規模:技術別
- 従来型血流感染症検査の市場規模
- 自動血流感染症検査の市場規模

・世界の血流感染症検査市場規模:技法別
- 培養法の市場規模
- 分子法の市場規模
- プロテオミクス法の市場規模

・世界の血流感染症検査市場規模:用途別
- 細菌における市場規模
- 真菌における市場規模
- マイコバクテリアにおける市場規模

・世界の血流感染症検査市場規模:地域別
- 北米の血流感染症検査市場規模
- ヨーロッパの血流感染症検査市場規模
- アジア太平洋の血流感染症検査市場規模
- 中南米の血流感染症検査市場規模
- 中東/アフリカの血流感染症検査市場規模

・競争状況
・企業情報

According to Research Dive analysis, the global blood stream infection testing market size market is anticipated to generate a revenue of $10,540.8 million by 2030, increasing from $5,173.1million in 2021, at a healthy CAGR of 8.3%.

COVID-19 Impact on the Global Blood Stream Infection Testing Market
As a result of the COVID-19 outbreak in 2020, government officials around the world implemented a variety of measures to limit the spread of COVID-19, including travel bans and restrictions, quarantines, shelter-in-place, stay-at-home or total lock-down orders, and business limitations and shutdowns. COVID-19 created significant volatility, uncertainty, and global economic disruption, resulting in a potentially long-lasting economic slowdown and had a negative impact on operations, supply chains, and distribution systems. The Blood Stream infection testing saw positive impact despite COVID-19 restriction and lockdown.
However, the Blood Stream infection testing market saw rise in late 2020 and 2021 due to rise in incidence rate mucormycosis in the COVID-19 patient. The blood cultures were used to identify and detect the mucormycosis infection.

Blood Stream Infection Testing Market Analysis
Bacteremia is most commonly diagnosed through blood culture, which involves incubating a sample of blood drawn from a vein via needle puncture with a medium that promotes bacterial growth. If bacteria are present in the Blood Stream when the sample is taken, they will multiply and can thus be detected. Blood Stream infection testing refers to the service of testing the blood for infections provided by healthcare centers, hospitals, or laboratories. The primary goal of the testing is to identify the bacteria or organism that is causing the blood infection.
When a bacterial, fungal, or viral infection is identified in the blood, it is called a blood stream infection. The problem becomes obvious when an infection enters the blood stream of any area of the body. Blood stream infection testing is performed to identify the bacteria or organisms responsible for the infection. Rising population is leading to overcrowding, which allows the spread of spread of such infections

However, the market revenue growth is also expected to be hampered due to lack of skill among healthcare professionals in emerging regions and other resource-poor nations.

Several technologically advanced device that offer improved methods for detecting bacteria in the blood stream have recently been introduced to the market. These cutting-edge technologies are predicted to compete with traditional devices and materials such as polystainers and microscopes in the market, slowing the expansion of traditional blood culture testing products. Key players will need to vary their product range by implementing new technologies in order to retain a position in the market. For key players with an established portfolio of conventional items, this will be a difficult task.

Based on product, the consumables sub-segment is anticipated to have dominant market share and generate a revenue of $8,505.3 million by 2030. Blood culture media, assay kits and reagents, and blood culture accessories are part of the consumables sub-segments. Aerobic blood culture media, pediatric aerobic blood culture media, anaerobic blood culture media, mycobacterial blood culture media, and fungi/yeast blood culture media are the subcategories of blood culture media.

Based on technique, the automated sub-segment is expected to show fastest in blood stream infection testing market and generate a revenue of $3,280.1 million by 2030. Rising government spending on healthcare infrastructure improvements, as well as increasing presence of independent laboratories in countries such as India, China, Mexico, and South Africa, are the primary factors driving demand for blood stream infection testing.

Based on technology, the culture-based sub-segment is expected to be dominant in blood stream infection testing market share and generate a revenue of $6,092.1 million by 2030. An increase in R&D activities to improve novel blood culture tests, as well as presence of major players operating in the region, are expected to drive revenue growth of the blood culture test market.

Based on application, the bacterial sub-segment is expected to be dominant in blood stream infection testing market share and generate a revenue of $5,776.6 million by 2030. Sepsis is regarded as one of the most common bacterial infections. Increased cases of sepsis around the world are expected to be the primary driving factor for the sub-segment growth.

Based on end-user, the hospitals sub-segment is expected to be dominant in blood stream infection testing market share and generate a revenue of $5,247.1 million by 2030. Due to an increase in awareness and acceptance of novel diagnostic methods in hospitals and laboratories, robust economic growth and increased demand for advanced healthcare facilities are all contributing to the market growth.

Based on geographical scope, the North America region market is anticipated to rise at a growth rate of 7.8% by 2030 from the revenue generated in 2021. Infections of the blood stream are major causes of morbidity and mortality. Death rates from blood stream infections can be compared to those from stroke, acute myocardial infarction, and trauma. However, the public health threat of blood stream infection has received inadequate attention in North America. People are vulnerable to infections such as flu, pneumonia, and diarrhea as a result of poor living conditions. The major driving factors for the regional market in the estimated period are governing bodies taking various precautionary measures and increasing their spending on improving healthcare infrastructure.

The companies involved in the global blood stream infection testing market are Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Becton Dickinson, bioMérieux SA, Cepheid, Luminex Corporation, Accelerate Diagnostics Inc., AdvanDX, and Bruker Corp.

❖ レポートの目次 ❖

1.Research Methodology

1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters
1.5.Market size estimation

1.5.1.Top-down approach
1.5.2.Bottom-up approach

2.Report Scope

2.1.Market definition
2.2.Key objectives of the study
2.3.Report overview
2.4.Market segmentation
2.5.Overview of the impact of COVID-19 on global blood stream infection testing market

3.Executive Summary

4.Market Overview

4.1.Introduction

4.2.Growth impact forces

4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunities

4.3.Market value chain analysis

4.3.1.List of raw material suppliers
4.3.2.List of manufacturers
4.3.3.List of distributors

4.4.Innovation & sustainability matrices

4.4.1.Technology matrix
4.4.2.Regulatory matrix

4.5.Porter’s five forces analysis

4.5.1.Bargaining power of suppliers
4.5.2.Bargaining power of consumers
4.5.3.Threat of substitutes
4.5.4.Threat of new entrants
4.5.5.Competitive rivalry intensity

4.6.PESTLE analysis

4.6.1.Political
4.6.2.Economical
4.6.3.Social
4.6.4.Technological
4.6.5.Environmental

4.7.Impact of COVID-19 on blood stream infection testing market

4.7.1.Pre-covid market scenario
4.7.2.Post-covid market scenario

5.Blood Stream Infection Testing Market Analysis, by Product

5.1.Overview

5.2.Consumables

5.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
5.2.2.Market size analysis, by region, 2021-2030
5.2.3.Market share analysis, by country, 2021-2030

5.3.Instruments

5.3.1.Definition, key trends, growth factors, and opportunities, 2021-2030
5.3.2.Market size analysis, by region, 2021-2030
5.3.3.Market share analysis, by country, 2021-2030

5.4.Software & Services

5.4.1.Definition, key trends, growth factors, and opportunities, 2021-2030
5.4.2.Market size analysis, by region, 2021-2030
5.4.3.Market share analysis, by country, 2021-2030

5.5.Research Dive Exclusive Insights

5.5.1.Market attractiveness, 2021-2030
5.5.2.Competition heatmap, 2021-2030

6.Blood Stream Infection Testing Market Analysis, by Technique

6.1.Conventional

6.1.1.Definition, key trends, growth factors, and opportunities, 2021-2030
6.1.2.Market size analysis, by region, 2021-2030
6.1.3.Market share analysis, by country, 2021-2030

6.2.Automated

6.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
6.2.2.Market size analysis, by region, 2021-2030
6.2.3.Market share analysis, by country, 2021-2030

6.3.Research Dive Exclusive Insights

6.3.1.Market attractiveness, 2021-2030
6.3.2.Competition heatmap, 2021-2030

7.Blood Stream Infection Testing Market Analysis, by Technology

7.1.Culture-based

7.1.1.Definition, key trends, growth factors, and opportunities, 2021-2030
7.1.2.Market size analysis, by region, 2021-2030
7.1.3.Market share analysis, by country, 2021-2030

7.2.Molecular

7.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
7.2.2.Market size analysis, by region, 2021-2030
7.2.3.Market share analysis, by country, 2021-2030

7.3.Proteomic

7.3.1.Definition, key trends, growth factors, and opportunities, 2021-2030
7.3.2.Market size analysis, by region, 2021-2030
7.3.3.Market share analysis, by country, 2021-2030

7.4.Research Dive Exclusive Insights

7.4.1.Market attractiveness, 2021-2030
7.4.2.Competition heatmap, 2021-2030

8.Blood Stream Infection Testing Market Analysis, by Application

8.1.Bacterial

8.1.1.Definition, key trends, growth factors, and opportunities, 2021-2030
8.1.2.Market size analysis, by region, 2021-2030
8.1.3.Market share analysis, by country, 2021-2030

8.2.Fungal

8.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
8.2.2.Market size analysis, by region, 2021-2030
8.2.3.Market share analysis, by country, 2021-2030

8.3.Mycobacterial

8.3.1.Definition, key trends, growth factors, and opportunities, 2021-2030
8.3.2.Market size analysis, by region, 2021-2030
8.3.3.Market share analysis, by country, 2021-2030

8.4.Research Dive Exclusive Insights

8.4.1.Market attractiveness, 2021-2030
8.4.2.Competition heatmap, 2021-2030

9.Blood Stream Infection Testing Market Analysis, by End-user

9.1.Hospitals

9.1.1.Definition, key trends, growth factors, and opportunities, 2021-2030
9.1.2.Market size analysis, by region, 2021-2030
9.1.3.Market share analysis, by country, 2021-2030

9.2.Independent Diagnostics Centers

9.2.1.Definition, key trends, growth factors, and opportunities, 2021-2030
9.2.2.Market size analysis, by region, 2021-2030
9.2.3.Market share analysis, by country, 2021-2030

9.3.Others

9.3.1.Definition, key trends, growth factors, and opportunities, 2021-2030
9.3.2.Market size analysis, by region, 2021-2030
9.3.3.Market share analysis, by country, 2021-2030

9.4.Research Dive Exclusive Insights

9.4.1.Market attractiveness, 2021-2030
9.4.2.Competition heatmap, 2021-2030

10.Blood Stream Infection Testing Market, by Region

10.1.North America

10.1.1.U.S.

10.1.1.1.Market size analysis, by Product, 2021-2030
10.1.1.2.Market size analysis, by Technique, 2021-2030
10.1.1.3.Market size analysis, by Technology, 2021-2030
10.1.1.4.Market size analysis, by Application, 2021-2030
10.1.1.5.Market size analysis, by End-user, 2021-2030

10.1.2.Canada

10.1.2.1.Market size analysis, by Product, 2021-2030
10.1.2.2.Market size analysis, by Technique, 2021-2030
10.1.2.3.Market size analysis, by Technology, 2021-2030
10.1.2.4.Market size analysis, by Application, 2021-2030
10.1.2.5.Market size analysis, by End-user, 2021-2030

10.1.3.Mexico

10.1.3.1.Market size analysis, by Product, 2021-2030
10.1.3.2.Market size analysis, by Technique, 2021-2030
10.1.3.3.Market size analysis, by Technology, 2021-2030
10.1.3.4.Market size analysis, by Application, 2021-2030
10.1.3.5.Market size analysis, by End-user, 2021-2030

10.1.4.Research Dive Exclusive Insights

10.1.4.1.Market attractiveness, 2021-2030
10.1.4.2.Competition heatmap, 2021-2030

10.2.Europe

10.2.1.Germany

10.2.1.1.Market size analysis, by Product, 2021-2030
10.2.1.2.Market size analysis, by Technique, 2021-2030
10.2.1.3.Market size analysis, by Technology, 2021-2030
10.2.1.4.Market size analysis, by Application, 2021-2030
10.2.1.5.Market size analysis, by End-user, 2021-2030

10.2.2.U.K.

10.2.2.1.Market size analysis, by Product, 2021-2030
10.2.2.2.Market size analysis, by Technique, 2021-2030
10.2.2.3.Market size analysis, by Technology, 2021-2030
10.2.2.4.Market size analysis, by Application, 2021-2030
10.2.2.5.Market size analysis, by End-user, 2021-2030

10.2.3.France

10.2.3.1.Market size analysis, by Product, 2021-2030
10.2.3.2.Market size analysis, by Technique, 2021-2030
10.2.3.3.Market size analysis, by Technology, 2021-2030
10.2.3.4.Market size analysis, by Application, 2021-2030
10.2.3.5.Market size analysis, by End-user, 2021-2030

10.2.4.Spain

10.2.4.1.Market size analysis, by Product, 2021-2030
10.2.4.2.Market size analysis, by Technique, 2021-2030
10.2.4.3.Market size analysis, by Technology, 2021-2030
10.2.4.4.Market size analysis, by Application, 2021-2030
10.2.4.5.Market size analysis, by End-user, 2021-2030

10.2.5.Italy

10.2.5.1.Market size analysis, by Product, 2021-2030
10.2.5.2.Market size analysis, by Technique, 2021-2030
10.2.5.3.Market size analysis, by Technology, 2021-2030
10.2.5.4.Market size analysis, by Application, 2021-2030
10.2.5.5.Market size analysis, by End-user, 2021-2030

10.2.6.Rest of Europe

10.2.6.1.Market size analysis, by Product, 2021-2030
10.2.6.2.Market size analysis, by Technique, 2021-2030
10.2.6.3.Market size analysis, by Technology, 2021-2030
10.2.6.4.Market size analysis, by Application, 2021-2030
10.2.6.5.Market size analysis, by End-user, 2021-2030

10.2.7.Research Dive Exclusive Insights

10.2.7.1.Market attractiveness, 2021-2030
10.2.7.2.Competition heatmap, 2021-2030

10.3.Asia-Pacific

10.3.1.China

10.3.1.1.Market size analysis, by Product, 2021-2030
10.3.1.2.Market size analysis, by Technique, 2021-2030
10.3.1.3.Market size analysis, by Technology, 2021-2030
10.3.1.4.Market size analysis, by Application, 2021-2030
10.3.1.5.Market size analysis, by End-user, 2021-2030

10.3.2.Japan

10.3.2.1.Market size analysis, by Product, 2021-2030
10.3.2.2.Market size analysis, by Technique, 2021-2030
10.3.2.3.Market size analysis, by Technology, 2021-2030
10.3.2.4.Market size analysis, by Application, 2021-2030
10.3.2.5.Market size analysis, by End-user, 2021-2030

10.3.3.India

10.3.3.1.Market size analysis, by Product, 2021-2030
10.3.3.2.Market size analysis, by Technique, 2021-2030
10.3.3.3.Market size analysis, by Technology, 2021-2030
10.3.3.4.Market size analysis, by Application, 2021-2030
10.3.3.5.Market size analysis, by End-user, 2021-2030

10.3.4.Australia

10.3.4.1.Market size analysis, by Product, 2021-2030
10.3.4.2.Market size analysis, by Technique, 2021-2030
10.3.4.3.Market size analysis, by Technology, 2021-2030
10.3.4.4.Market size analysis, by Application, 2021-2030
10.3.4.5.Market size analysis, by End-user, 2021-2030

10.3.5.South Korea

10.3.5.1.Market size analysis, by Product, 2021-2030
10.3.5.2.Market size analysis, by Technique, 2021-2030
10.3.5.3.Market size analysis, by Technology, 2021-2030
10.3.5.4.Market size analysis, by Application, 2021-2030
10.3.5.5.Market size analysis, by End-user, 2021-2030

10.3.6.Rest of Asia-Pacific

10.3.6.1.Market size analysis, by Product, 2021-2030
10.3.6.2.Market size analysis, by Technique, 2021-2030
10.3.6.3.Market size analysis, by Technology, 2021-2030
10.3.6.4.Market size analysis, by Application, 2021-2030
10.3.6.5.Market size analysis, by End-user, 2021-2030

10.3.7.Research Dive Exclusive Insights

10.3.7.1.Market attractiveness, 2021-2030
10.3.7.2.Competition heatmap, 2021-2030

10.4.LAMEA

10.4.1.Brazil

10.4.1.1.Market size analysis, by Product, 2021-2030
10.4.1.2.Market size analysis, by Technique, 2021-2030
10.4.1.3.Market size analysis, by Technology, 2021-2030
10.4.1.4.Market size analysis, by Application, 2021-2030
10.4.1.5.Market size analysis, by End-user, 2021-2030

10.4.2.Saudi Arabia

10.4.2.1.Market size analysis, by Product, 2021-2030
10.4.2.2.Market size analysis, by Technique, 2021-2030
10.4.2.3.Market size analysis, by Technology, 2021-2030
10.4.2.4.Market size analysis, by Application, 2021-2030
10.4.2.5.Market size analysis, by End-user, 2021-2030

10.4.3.UAE

10.4.3.1.Market size analysis, by Product, 2021-2030
10.4.3.2.Market size analysis, by Technique, 2021-2030
10.4.3.3.Market size analysis, by Technology, 2021-2030
10.4.3.4.Market size analysis, by Application, 2021-2030
10.4.3.5.Market size analysis, by End-user, 2021-2030

10.4.4.South Africa

10.4.4.1.Market size analysis, by Product, 2021-2030
10.4.4.2.Market size analysis, by Technique, 2021-2030
10.4.4.3.Market size analysis, by Technology, 2021-2030
10.4.4.4.Market size analysis, by Application, 2021-2030
10.4.4.5.Market size analysis, by End-user, 2021-2030

10.4.5.Rest of LAMEA

10.4.5.1.Market size analysis, by Product, 2021-2030
10.4.5.2.Market size analysis, by Technique, 2021-2030
10.4.5.3.Market size analysis, by Technology, 2021-2030
10.4.5.4.Market size analysis, by Application, 2021-2030
10.4.5.5.Market size analysis, by End-user, 2021-2030

10.4.6.Research Dive Exclusive Insights

10.4.6.1.Market attractiveness, 2021-2030
10.4.6.2.Competition heatmap, 2021-2030

11.Competitive Landscape

11.1.Top winning strategies, 2021

11.1.1.By strategy
11.1.2.By year
11.2.Strategic overview
11.3.Market share analysis, 2021

12.Company Profiles

12.1. Thermo Fisher Scientific

12.1.1.Overview
12.1.2.Business segments
12.1.3.Product portfolio
12.1.4.Financial performance
12.1.5.Recent developments
12.1.6.SWOT analysis

12.2.F. Hoffmann-La Roche Ltd

12.2.1.Overview
12.2.2.Business segments
12.2.3.Product portfolio
12.2.4.Financial performance
12.2.5.Recent developments
12.2.6.SWOT analysis

12.3.Abbott

12.3.1.Overview
12.3.2.Business segments
12.3.3.Product portfolio
12.3.4.Financial performance
12.3.5.Recent developments
12.3.6.SWOT analysis

12.4. BD

12.4.1.Overview
12.4.2.Business segments
12.4.3.Product portfolio
12.4.4.Financial performance
12.4.5.Recent developments
12.4.6.SWOT analysis

12.5.BIOMÉRIEUX

12.5.1.Overview
12.5.2.Business segments
12.5.3.Product portfolio
12.5.4.Financial performance
12.5.5.Recent developments
12.5.6.SWOT analysis

12.6.Cepheid.

12.6.1.Overview
12.6.2.Business segments
12.6.3.Product portfolio
12.6.4.Financial performance
12.6.5.Recent developments
12.6.6.SWOT analysis

12.7.Luminex Corporation

12.7.1.Overview
12.7.2.Business segments
12.7.3.Product portfolio
12.7.4.Financial performance
12.7.5.Recent developments
12.7.6.SWOT analysis

12.8.Accelerate Diagnostics

12.8.1.Overview
12.8.2.Business segments
12.8.3.Product portfolio
12.8.4.Financial performance
12.8.5.Recent developments
12.8.6.SWOT analysis

12.9.AdvanDX

12.9.1.Overview
12.9.2.Business segments
12.9.3.Product portfolio
12.9.4.Financial performance
12.9.5.Recent developments
12.9.6.SWOT analysis

12.10.Bruker

12.10.1.Overview
12.10.2.Business segments
12.10.3.Product portfolio
12.10.4.Financial performance
12.10.5.Recent developments
12.10.6.SWOT analysis

13.Appendix

13.1.Parent & peer market analysis
13.2.Premium insights from industry experts
13.3.Related reports



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 血流感染症検査の世界市場2022-2030:機会分析・産業予測(Blood Stream Infection Testing Market by Product (Instruments, Consumables, and Software & Services), Technique (Conventional and Automated), and Technology (Culture-based, Molecular, and Proteomic), Application (Bacterial, Fungal, and Mycobacterial), End-user (Hospitals, Independent Diagnostics Centers, and Others), and Regional Analysis (North America, Europe, Asia-Pacific and LAMEA): Global Opportunity Analysis and Industry Forecast, 2022–2030)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆